-- CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:
In a surprise announcement today, Sun Pharma, India's largest drugmaker and the fourth-largest specialty generic pharmaceutical firm globally, announced its agreement to acquire Organon for $14.00 per share in an all-cash deal valued at $11.75B enterprise value. The transaction, slated to close in early 2027, is expected to create a top 25 global pharmaceutical firn with ~$12.4B in combined revenue, making Sun Pharma a top three player in women's health, the seventh largest biosimilars company globally. We think this acquisition makes strategic sense as Organon has been facing performance and governance issues in the past year after an internal investigation found improper wholesale practices in the U.S. related to Organon's key contraceptive Nexplanon and the abrupt departure of the former CEO K. Ali. Shares of OGN jumped by 17% today after the news. We raise our target to $14.00 from $7.00, based on a P/E of 3.8x our 2027 EPS estimate.We keep our 2026 EPS estimate at $3.62 and our 2027 EPS estimate at $3.71.